Alerta

TLR7/8 ANTAGONISTS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTIONS

Resumen de: EP4830786A2

0001 The present invention encompasses TLR7/8 antagonists for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.

BROADLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND SARS-COV VARIANTS

Resumen de: MX2026005520A

Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.

POINT-OF-CARE ON-CHIP IGRA DEVICE AND METHOD FOR MEASURING SPECIFIC T CELL ACTIVATION

Resumen de: US20260328766A1

Method and device for detecting SARS-CoV-2 specific T-Cell interferon-gamma activation is described. By using a microfluidic chip to allow ELISpot interferon gamma release assays (IGRA) be performed using a small amount of fingerstick whole blood sample, fast results can be provided with minimal amount of blood sample.

ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF

Resumen de: US20260327292A1

Disclosed are antigen binding antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptide complexes; and methods of using such polypeptide complexes.

COMPOSITIONS AND METHODS FOR ASSESSING THE SEVERITY OF AND TREATING COVID-19

Resumen de: US20260328785A1

0000 The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods for assessing the severity of and treating severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) or COVID-19. In particular embodiments, a method for treating COVID-19 in a patient comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.

COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSE

Resumen de: WO2026222087A2

The invention relates to saponin matrix adjuvants comprising Matrix-A and Matrix-C particles at fixed weight ratios between about 70:30 to 10:90 (Matrix-A:Matrix-C), specifically about 60:40, 59:41, 58:42, 57:43, 56:44, 55:45, 54:46, 53:47, 52:48, 51:49, or 50:50, in contrast to conventional 85:15 Matrix-M adjuvant. Matrix-A and Matrix-C are cage-like particles formed from chromatographically separated Quillaja saponin fractions with cholesterol and phosphatidylcholine. At the disclosed ratios, the compositions unexpectedly enhance lysosomal targeting, lysosomal membrane permeabilization, antigen cross-presentation, and activation of antigen-presenting cells, yielding at least about 30–100% higher frequencies of antigen-specific CD8 T cells producing IFN-γ under comparable dosing conditions. The saponin matrix compositions can be formulated with viral antigens (for example SARS-CoV-2 spike, RSV F0, PIV3, hMPV F) or tumor antigens (including defined tumor-associated antigens and neoantigens) to provide vaccines that induce protective antiviral immunity and therapeutic antitumor responses using manufacturing processes compatible with existing Matrix platforms.

PROBIOTIC COMPOSITION FOR THE TREATMENT OF COVID-19

Resumen de: WO2022171304A1

A probiotic composition comprising Lactobacillus plantarum CECT 30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483 is provided. The probiotic composition is useful in treating, preventing, or ameliorating COVID-19 or symptoms, complications and/or sequela thereof, and other infectious diseases. It is also useful in enhancing the immune response.

IMMUNOLOGICALLY INACTIVE POLY (ETHYLENE GLYCOL) POLYMER DERIVATIVES AND BIOCONJUGATES THEREOF FOR USE AS ALTERNATIVE IN PEGYLATED THERAPEUTICS, PROCESSES FOR THEIR PREPARATION AND THEIR USE

Resumen de: US20260325627A1

0000 Immunological inactive polyether polymers represented by the following formula I: 0000 0000 wherein at least 3% of the residues R include ethylene oxide side chains, oligo(ethylene oxide) side chains and/or glycerol ether side chains and at least 3% of the residues R are hydrogen and R may also be a C1 to C3-alkyloxymethyl side chain. Further, a process for the preparation of the polymers. Finally, the use of the polymers for the preparation of conjugates, especially bioconjugates and the conjugates themselves as alternative for PEGylated therapeutics. The conjugates may include bioactive compounds and/or lipids. They are especially useful for the preparation of vaccines, lipid particles, especially lipid nanoparticles and may be used for the preparation of vaccines against COVID-19.

METHOD FOR TREATING LONG-COVID INDUCED NEUROLOGIC DISEASES

Resumen de: US20260325548A1

A method of reducing neuroinflammation, tau accumulation, tau phosphorylation, and/or corticosterone secretion to treat or prevent Alzheimer's disease or related dementias, depression, and/or anxiety in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Glucocorticoid receptor antagonists such as mifepristone and nanodendriplexes comprising RNA interference agents targeting FKBP5, IFI16, or a combination thereof exhibit efficacy in reducing abnormal tau accumulation and neuroinflammation in Cov-2-infected patients to reduce neurological symptoms associated with infection.

RECOMBINANT MURINE PNEUMONIA VIRUS EXPRESSING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE PROTEIN

Resumen de: US20260325625A1

0000 Recombinant murine pneumonia viruses (rMPV) expressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein and their use as live-attenuated virus vaccines against SARS-CoV-2 are described. The rMPV expressing S protein are safe, immunogenic, and efficacious for protecting a subject against SARS-CoV-2 infection and disease, as demonstrated in a non-human primate model. The rMPV induce a strong systemic and mucosal antibody response against the SARS-CoV-2 S protein. Furthermore, a single dose of the live-attenuated rMPV induced strong protection against SARS-CoV-2 challenge, while two doses were fully protective.

HIP/PAP PROTEIN OR A DERIVATIVE THEREOF FOR TREATING A COGNITIVE DISORDER ASSOCIATED WITH ANXIETY DISORDER

Resumen de: US20260327279A1

0000 A HIP/PAP protein, or a derivative thereof, is provided for the treatment and prevention cognition conditions. In particular the HIP/PAP protein, or a derivative thereof is for the treatment of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s). The HIP/PAP protein, or a derivative thereof is also alleviating cognitive deficit in an individual affected by a disorder selected from Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection, and also in the prevention and/or treatment of diet induced cognitive and anxiety deficits in an individual in need thereof, and in particular high fat diet induced cognitive and anxiety deficits.

SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AS COMPOSITION FOR TREATMENT OR PREVENTION OF NOVEL CORONAVIRUS INFECTION DISEASES

Resumen de: US20260327238A1

The present invention provides a compound useful for the treatment or prevention of SARS-CoV-2 novel coronavirus infection.The present invention relates to a compound represented by formula (I), its enantiomer, or a pharmaceutically acceptable salt thereof:wherein ring A, R1 and R7, R2 and R4, X and Y, as well as Z are according to the definitions as described in the specification;use thereof for the treatment or prevention of SARS-CoV-2 novel coronavirus infection; and pharmaceutical compositions comprising the same.

Post COVID-19 Vaccine Remedies

Resumen de: US20260325553A1

0000 Methods and compositions to lessen toxicities in COV19 vaccine aftermath. These involve administering synergistic or complementary formulations of early detoxification agents, antioxidants, anti-inflammatories, pro-immunity agents, gp41/gp120 inhibitors, nAChR/NAD<+>, boosters, ACE-2 modulators, anticoagulants and other micronutrients, vitamins, plant-derived compounds and selections from pertinent, major drug classes. tailored to address post-vaccination complications effectively.

Antibody against Novel Coronavirus, and Kit for Novel Coronavirus Detection

Resumen de: US20260327291A1

An antibody against novel coronavirus and a kit for novel coronavirus detection. The antibody against novel coronavirus includes a heavy chain complementarity determinant region and a light chain complementarity determinant region. The antibody has good affinity for N protein of novel coronavirus, and has good sensitivity and specificity for detecting the novel coronavirus. More antibody options are provided for detecting the novel coronavirus.

METHODS AND COMPOSITIONS FOR CHRONIC INFLAMMATION USING COLCHICINE

Resumen de: WO2026220159A1

Pharmaceutical compositions of colchicine for once-daily oral administration are provided for use in the treatment of chronic inflammation, including inflammation arising after COVID-19 vaccination and/or COVID-19 infection (Long COVID). The formulations comprise, in some embodiments, an immediate-release component and/or a sustained-release component, which is tailored to achieve a desired pharmacokinetic profile suitable for long-term anti-inflammatory therapy. The disclosed compositions are designed to reduce systemic levels of key inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP), C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and myeloperoxidase (MPO), and to alleviate clinical manifestations of persistent inflammation, including vaccine-associated myocarditis, pericarditis, or other inflammatory sequelae. Methods of treating post-vaccination and/or post-infection inflammatory syndromes, improving quality of life, and reducing hospitalization risk in mammalian subjects are also provided.

AN ANTIBODY OR ANTIGEN BINDING FRAGMENT

Resumen de: WO2026220162A1

The present invention relates to an antibody molecule or an antigen binding fragment, which targets a SARS-related coronavirus, for example SARS-CoV-2 and variants thereof, suitably which is bovine derived. The invention further relates to a method of producing these antibody molecules and/or antigen binding fragments, and the uses of these antibody molecules and/or antigen binding fragments. The invention also relates to nucleic acid molecules encoding the molecules and/or fragments, and expression vectors and hosts cells comprising the same.

PLPRO INHIBITORS AND METHODS OF USING THE SAME

Resumen de: WO2026222182A1

Disclosed herein is a library of SARS-CoV-2 PLpro inhibitors. The compounds described herein represent potent inhibitors of PLpro with activity translating to live virus assays in mammalian and human host cells. Also provided herein are methods of using the PLpro inhibitors for preventing or treating infections, diseases, and/or symptoms caused by exposure to a coronavirus, such as SARS-CoV-2, SARS-CoV-1, and MERS in a subject in need thereof.

DIAGNOSTIC TESTING APPARATUS AND SYSTEM

Resumen de: US20260328767A1

0000 A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.

INFECTIOUS DISEASE ANTIBODIES AND USES THEREOF

Resumen de: US20260327293A1

0000 Compositions and methods involving effector cells armed with antiviral antibodies are disclosed herein. Such compositions may also include additional antiviral treatments and may be used, for example, to treat subjects having a viral infection (e.g., SARS-COV-2).

METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH SARS-COV-2

Resumen de: EP4825448A2

0001 Provided herein are methods of treating or preventing SARS-CoV-2 infection comprising modulating interactions between the SARS-CoV-2 spike protein and plasma membrane-expressed host cell proteins, as well as methods of identifying modulators of such interactions.

Sensor electrode for use in bioelectrochemical diagnostics of SARS-CoV-2 coronavirus, a method for producing the sensor electrode for use in bioelectrochemical diagnostics of SARS-CoV-2 coronavirus, and a method for bioelectrochemical detection of SARS-CoV-2 coronavirus

Resumen de: PL451832A1

Przedmiotem zgłoszenia jest elektroda czujnikowa do zastosowania w diagnostyce bioelektrochemicznej koronawirusa SARS-CoV-2, która charakteryzuje się tym, że stanowi podłoże krzemowe z naniesioną warstwą diamentu domieszkowanego borem (BDD), która zbudowana jest z polidopaminy PDA i polizwitterjonu PZ z receptorami ACE2 zakotwiczonymi na powierzchni BDD za pomocą oddziaływań niekowalencyjnych elektrostatycznych i dyspersyjnych wytworzonych między merami dopaminy, polizwitterjonu i ACE-2 a podłożem BDD w trakcie procesu elektropolimeryzacji, przy czym ACE-2 jest doczepiony do powierzchni elektrody i jest związany za pomocą polimerów PDA-PZ. Przedmiotem zgłoszenia jest także sposób otrzymywania elektrody czujnikowej do zastosowania w diagnostyce bioelektrochemicznej koronawirusa SARS-COV-2 oraz sposób detekcji bioelektrochemicznej koronawirusa SARS-COV-2.

SARS-COV2 NEUTRALIZING SINGLE DOMAIN ANTIBODY CONSTRUCTS

Resumen de: US20260317403A1

0000 Antibodies, including single-domain antibodies, that bind to SARS-CoV2 virus and methods of treatment using single-domain antibodies that bind to SARS-CoV2 virus are provided.

METHODS AND SYSTEMS FOR RNA SEQUENCING AND ANALYSIS

Resumen de: US20260317820A1

0000 Aspects of the present disclosure are directed to methods and systems for sample collection, tRNA sequencing, and diagnosis, prognosis, and treatment of viral infections such as SARS-CoV-2. Disclosed herein are methods for tRNA sequencing and analysis, including obtaining a tRNA profile of RNA from a nasopharyngeal sample. A tRNA profile may include abundance, fragmentation, and/or modification information for a plurality of tRNAs from a sample. Also disclosed are methods for diagnosis, prognosis, and/or treatment of a viral infection (e.g., SARS-CoV-2 infection) based on abundance, fragmentation, and/or modification information for one or more tRNAs from a subject having or suspected of having a viral infection.

VACCINE USES

Resumen de: WO2026215512A1

The present disclosure relates to methods of immunizing individuals for prophylaxis or prevention of an infection by a virus (e.g., a sarbecoronavirus virus such as a SARS-CoV-2 virus) and methods of inducing a pan-variant immune responses against a virus using low doses of vaccines.

COMPOSITIONS AND METHODS FOR IMPROVING NITRIC OXIDE LEVELS IN INTRAORAL, NASAL AND/OR NASOPHARYNGEAL AREA

Nº publicación: US20260315522A1 15/10/2026

Solicitante:

GREEN SHAWN J [US]
GREEN Shawn J.

Resumen de: US20260315522A1

The present disclosure relates to improving oral-nasal health by increasing, oral, intraoral and nasal cavity nitric oxide levels using a novel prebiotic nitrate-formulated chewing gum composition, together with an optional step comprising the use of saliva test strip to monitor pH, nitrate, and nitrite. The novel gum compositions and methods of the invention result in improved nitric oxide bioavailability and thereby increase antimicrobial nitric oxide levels beneficial for reducing dental caries, periodontitis, and nasopharyngitis, as well as reduce transmission of aerosolized viral particles acutely sensitive to nitric oxide, including SARS-COV.